Kigali, Rwanda and San Francisco, USA -- Bio Usawa congratulates RIIO’s October, 2025 graduating class, as well as Dr. Wanjiku (Ciku) Mathenge, the Institute’s Founder and Director of Training and Research, and President of the African Ophthalmology Council.

This commencement marks the 3rd graduation from RIIO’s pioneering residency training program in ophthalmology, which has now produced 13 ophthalmologists from 4 countries.

RIIO was founded in 2011 to shape the future of eye care in Africa through state-of-the-art training, continuing education and first-in-Africa advanced level accreditation from the Ophthalmology Foundation.

Bio Usawa looks forward to following the successful careers of the graduates as we share the goal of improving eye health through making safe, affordable, and high-quality biotherapies more accessible to patients Africa and beyond. 

About Bio Usawa Inc.

Bio Usawa is Rwanda's leading biotechnology company dedicated to democratizing access to life-saving biopharmaceuticals across Africa. Founded on the principle that geographic location should not determine healthcare outcomes, the company specializes in developing and manufacturing affordable, high-quality monoclonal antibodies targeting cancer, diabetes complications, infectious diseases, and autoimmune conditions. Bio Usawa's leadership team brings decades of experience from leading global biotech companies and international regulatory agencies.